There are currently no widely publicized or open class action lawsuits specifically targeting Medicare coverage of new Alzheimer’s drugs such as Leqembi or Aduhelm. While Alzheimer’s treatments have generated significant attention due to their high costs and complex coverage issues, the legal actions involving Medicare and Alzheimer’s drugs have so far been more focused on broader Medicare policies, pricing disputes, or coverage denials rather than class actions directly related to these new medications.
Medicare’s coverage of Alzheimer’s drugs has been controversial, especially since the approval of drugs like Aduhelm and Leqembi, which are expensive and have raised questions about their clinical benefits and cost-effectiveness. Medicare Part B typically covers certain Alzheimer’s drugs administered in clinical settings, but coverage decisions and reimbursement rates have been subject to scrutiny and debate. Some beneficiaries and advocacy groups have expressed concerns about access, affordability, and the criteria Medicare uses to determine coverage eligibility.
Although there have been class action lawsuits related to Medicare in other contexts—such as disputes over drug pricing, improper billing, or denial of care—none have emerged prominently as open class actions specifically challenging Medicare’s coverage policies for new Alzheimer’s drugs. For example, lawsuits have addressed issues like Medicare’s drug price negotiation processes or insurer denials of care using AI algorithms, but these are not directly about Alzheimer’s drug coverage.
The complexity of Medicare’s coverage rules, combined with the evolving landscape of Alzheimer’s drug approvals and pricing, means that legal challenges could arise in the future. However, as of now, no major open class actions are known to be filed that focus exclusively on Medicare’s coverage of new Alzheimer’s medications.
In summary, while Alzheimer’s drugs and their Medicare coverage remain a hot topic in healthcare policy and patient advocacy, there are no notable open class action lawsuits specifically addressing Medicare’s coverage of these new treatments at this time. Legal actions related to Medicare tend to focus on broader systemic issues rather than on individual drug coverage disputes.
